Navidea Biopharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Download as PDF

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the Rodman & Renshaw 19th Annual Global Investment Conference, being held September 10-12, 2017, in New York, NY. Michael Goldberg, M.D., Chief Executive Officer of Navidea, will be giving a presentation and meeting with investors throughout the conference.

Event:

  Rodman & Renshaw 19th Annual Global Investment Conference

Date:

Tuesday, September 12, 2017

Time:

4:40pm ET

Location:

Lotte New York Palace, New York, NY
 

For investors attending the Rodman & Renshaw conference, please contact Navidea Investor Relations to schedule a meeting with Navidea management at tpatel@edisongroup.com or ir@navidea.com.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Events tab of the Investor Relations section of the Navidea website at www.navidea.com.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its ManoceptTM platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.
Jed Latkin, CFO/COO, 614-551-3416
jlatkin@navidea.com
or
Edison Advisors
Tirth Patel, 646-653-7035
tpatel@edisongroup.com

Source: Navidea Biopharmaceuticals, Inc.

Released September 8, 2017